« Return to News | CROs/Service Providers

GVK Bioscience’s Ahmedabad clinical pharmacology unit clears FDA audit

Monday, July 30, 2012 09:52 AM

GVK Biosciences, an Asian CRO, announced that its Ahmedabad Clinical Pharmacology Unit has successfully cleared an FDA audit with zero 483s/observations from the agency. FDA visited and audited a First-to-File study for one of GVK BIO’s customers.

The GVK Ahmedabad facility, commissioned in 2010, has three clinics with 110 beds. The facility has been inspected and approved by drugs controller general of India, Anvisa-Brazil and Ministry of Health (MoH)-Turkey. The Ahmedabad facility carries out bioavailability and bioequivalence (BA/BE) studies that are submitted to various regulatory agencies including FDA, TGA (Australia), European Regulatory agencies, Health Canada, Anvisa-Brazil and MoH (Turkey).

“This is a clear testimony of the high standards of quality and processes followed at GVK BIO,” said Manni Kantipudi, CEO of GVK. “The sponsor can now carry out BA/BE studies at either of our sites—Ahmedabad or Hyderabad—with a wider choice of population and capacities”.

The Ahmedabad success comes on the heels of regulatory joint inspection by FDA, ANSM (France), AGES (Austria) and WHO, of the GVK Hyderabad facility. This inspection was the first joint inspection of a CRO by the four agencies. GVK received zero 483s by FDA in this joint inspection as well. The GVK BIO Hyderabad facility is a full service provider of BA/BE services with four clinics and 144 beds supported by a bioanalytical facility with 16 LC-MS/MS machines.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.